Mangalam Drugs & Organics Limited (MANGALAM.NS)
INR 80.98
(-1.51%)
INR 80.98
(-1.51%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.97 Billion INR | -4.84% |
| 2022 | 2.07 Billion INR | 16.76% |
| 2021 | 1.77 Billion INR | 34.86% |
| 2020 | 1.31 Billion INR | 4.07% |
| 2019 | 1.26 Billion INR | 11.78% |
| 2018 | 1.13 Billion INR | -13.35% |
| 2017 | 1.3 Billion INR | 24.75% |
| 2016 | 1.04 Billion INR | 6.75% |
| 2015 | 982.39 Million INR | -30.09% |
| 2014 | 1.4 Billion INR | 37.48% |
| 2013 | 1.02 Billion INR | 15.48% |
| 2012 | 885.15 Million INR | 5.52% |
| 2011 | 838.83 Million INR | 20.43% |
| 2010 | 696.55 Million INR | 27.77% |
| 2009 | 545.16 Million INR | 8.95% |
| 2008 | 500.35 Million INR | 26.42% |
| 2007 | 395.79 Million INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -1.35 Billion INR | -168.61% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 1.97 Billion INR | 0.0% |
| 2023 Q2 | 2.48 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 FY | 1.97 Billion INR | -4.84% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 2.07 Billion INR | 16.76% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 2.18 Billion INR | 0.0% |
| 2022 Q4 | 2.07 Billion INR | 0.0% |
| 2021 Q2 | 1.91 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 1.77 Billion INR | 34.86% |
| 2021 Q4 | 1.77 Billion INR | 0.0% |
| 2020 Q4 | 1.31 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 1.35 Billion INR | 0.0% |
| 2020 FY | 1.31 Billion INR | 4.07% |
| 2019 FY | 1.26 Billion INR | 11.78% |
| 2019 Q4 | 1.26 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 1.17 Billion INR | 0.0% |
| 2018 Q4 | 1.13 Billion INR | 0.0% |
| 2018 FY | 1.13 Billion INR | -13.35% |
| 2018 Q2 | 1.35 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 1.3 Billion INR | 24.75% |
| 2017 Q4 | 1.3 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 1.17 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 1.04 Billion INR | 6.75% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 1.19 Billion INR | 0.0% |
| 2016 Q4 | 1.04 Billion INR | 0.0% |
| 2015 Q4 | 982.39 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 1.06 Billion INR | 0.0% |
| 2015 FY | 982.39 Million INR | -30.09% |
| 2014 Q4 | 1.4 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 FY | 1.4 Billion INR | 37.48% |
| 2014 Q2 | 946.54 Million INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 FY | 1.02 Billion INR | 15.48% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 939.18 Million INR | 0.0% |
| 2013 Q4 | 1.02 Billion INR | 0.0% |
| 2012 FY | 885.15 Million INR | 5.52% |
| 2012 Q4 | 885.15 Million INR | 0.0% |
| 2011 Q4 | 838.83 Million INR | 0.0% |
| 2011 FY | 838.83 Million INR | 20.43% |
| 2010 FY | 696.55 Million INR | 27.77% |
| 2009 FY | 545.16 Million INR | 8.95% |
| 2008 FY | 500.35 Million INR | 26.42% |
| 2007 FY | 395.79 Million INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -14.756% |
| Aarti Drugs Limited | 11.5 Billion INR | 82.821% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 76.047% |
| Ajanta Pharma Limited | 10.71 Billion INR | 81.548% |
| Alembic Limited | 1.43 Billion INR | -38.001% |
| Alkem Laboratories Limited | 48.6 Billion INR | 95.934% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 87.856% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | 46.019% |
| Bal Pharma Limited | 2.51 Billion INR | 21.303% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -584.321% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | 6.285% |
| Brooks Laboratories Limited | 248.6 Million INR | -694.973% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -202.986% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | 43.624% |
| Divi's Laboratories Limited | 18.99 Billion INR | 89.593% |
| Eris Lifesciences Limited | 38.26 Billion INR | 94.836% |
| Granules India Limited | 22.95 Billion INR | 91.39% |
| Ind-Swift Limited | 13.45 Billion INR | 85.309% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -565.963% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 81.544% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 96.775% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -206.936% |
| Medicamen Biotech Limited | 940.36 Million INR | -110.164% |
| Medico Remedies Limited | 438.24 Million INR | -350.961% |
| Wockhardt Limited | 39.87 Billion INR | 95.043% |
| Orchid Pharma Limited | 3.84 Billion INR | 48.588% |
| RPG Life Sciences Limited | 1.38 Billion INR | -43.19% |
| Shilpa Medicare Limited | 12.93 Billion INR | 84.718% |
| Sigachi Industries Limited | 2.53 Billion INR | 21.924% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | 85.975% |
| Unichem Laboratories Limited | 8.06 Billion INR | 75.508% |
| Vaishali Pharma Limited | 371.16 Million INR | -432.464% |
| Wanbury Limited | 3.15 Billion INR | 37.37% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 97.247% |
| FDC Limited | 3.7 Billion INR | 46.719% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -152.137% |
| Bajaj HealthCare Limited | 4.86 Billion INR | 59.399% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 98.152% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | 61.854% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | 13.678% |
| Laurus Labs Limited | 42.71 Billion INR | 95.373% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 82.383% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -1136.81% |
| Hester Biosciences Limited | 3.59 Billion INR | 45.022% |
| Ipca Laboratories Limited | 33.74 Billion INR | 94.143% |
| Venus Remedies Limited | 1.39 Billion INR | -41.895% |
| ZIM Laboratories Limited | 2.08 Billion INR | 5.02% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 98.702% |
| Morepen Laboratories Limited | 4.45 Billion INR | 55.686% |
| Neuland Laboratories Limited | 5.49 Billion INR | 64.058% |
| Sequent Scientific Limited | 8.27 Billion INR | 76.115% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | 2.847% |
| Valiant Laboratories Limited | 1.05 Billion INR | -86.751% |
| Windlas Biotech Limited | 1.76 Billion INR | -12.118% |
| Hikal Limited | 12.99 Billion INR | 84.792% |
| Innova Captab Limited | 4.89 Billion INR | 59.666% |
| Procter & Gamble Health Limited | 2.56 Billion INR | 22.837% |
| Themis Medicare Limited | 1.88 Billion INR | -4.705% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | 68.773% |
| Mankind Pharma Limited | 23.87 Billion INR | 91.722% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 96.965% |
| Sakar Healthcare Limited | 1.26 Billion INR | -56.443% |
| Albert David Limited | 1.15 Billion INR | -71.837% |
| Lupin Limited | 96.23 Billion INR | 97.946% |
| Gufic Biosciences Limited | 5.59 Billion INR | 64.708% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 98.923% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -83.921% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -69.61% |
| Piramal Enterprises Limited | 560.47 Billion INR | 99.647% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 97.591% |
| NATCO Pharma Limited | 10.53 Billion INR | 81.235% |
| Suven Life Sciences Limited | 148.62 Million INR | -1229.766% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | 33.545% |
| Strides Pharma Science Limited | 37.68 Billion INR | 94.755% |
| Indoco Remedies Limited | 10.34 Billion INR | 80.891% |
| Alpa Laboratories Limited | 307.12 Million INR | -543.494% |
| Lasa Supergenerics Limited | 541.92 Million INR | -264.683% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | 49.233% |